Levafetamine
Alternative Names: C 105; L-alpha-methylphenethylamine; L-amfetamine; L-amfetamine sulfate; L-amphetamine; L-amphetamine sulfate; Levamfetamine; LevoamphetamineLatest Information Update: 02 Oct 2021
At a glance
- Originator Brown University; Sention
- Developer Cognition Pharmaceuticals
- Class Amphetamines; Antidementias; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Neurotransmitter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 19 Dec 2008 Interim efficacy and safety data from the phase II, NCT00529581 trial in patients with cognitive impairment due to multiple sclerosis (Cognition disorders) released by Cognition Pharmaceuticals
- 30 Apr 2008 Cognition Pharmaceuticals completes the phase II, NCT00529581 trial for cognitive impairment in patients with multiple sclerosis (Cognitive disorders) in USA
- 19 Jan 2005 Sention completes phase I trials in Cognitive disorders